Abstract: A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.

Abstract: A network device transmits data to a user equipment (UE) via a first Radio Access Network (RAN) using first Transmission Control Protocol (TCP) congestion control parameters. The network device receives a notification message indicating that the UE has moved from the first RAN to a second RAN. The network device modifies, responsive to receipt of the notification, the first TCP congestion control parameters to create second TCP congestion control parameters, where the first TCP congestion control parameters include a first slow start threshold (ssthresh), and wherein the second TCP congestion control parameters include a second ssthresh that is different than the first ssthresh. The network device transmits data to the UE via the second RAN using the second TCP congestion control parameters.

Abstract: A network device transmits data to a user equipment (UE) via a first Radio Access Network (RAN) using first Transmission Control Protocol (TCP) congestion control parameters. The network device receives a notification message indicating that the UE has moved from the first RAN to a second RAN. The network device modifies, responsive to receipt of the notification, the first TCP congestion control parameters to create second TCP congestion control parameters, where the first TCP congestion control parameters include a first slow start threshold (ssthresh), and wherein the second TCP congestion control parameters include a second ssthresh that is different than the first ssthresh. The network device transmits data to the UE via the second RAN using the second TCP congestion control parameters.

Abstract: A network device transmits data to a user equipment (UE) via a first Radio Access Network (RAN) using first Transmission Control Protocol (TCP) congestion control parameters. The network device receives a notification message indicating that the UE has moved from the first RAN to a second RAN, and modifies, responsive to receipt of the notification, the first TCP congestion control parameters to create second TCP congestion control parameters. The network device transmits data to the UE via the second RAN using the second TCP congestion control parameters.

Abstract: A network device transmits data to a user equipment (UE) via a first Radio Access Network (RAN) using first Transmission Control Protocol (TCP) congestion control parameters. The network device receives a notification message indicating that the UE has moved from the first RAN to a second RAN, and modifies, responsive to receipt of the notification, the first TCP congestion control parameters to create second TCP congestion control parameters. The network device transmits data to the UE via the second RAN using the second TCP congestion control parameters.

Abstract: A lightweight high-strength ceramsite, comprising solid raw materials and activator as the raw materials, which can be respectively expressed in parts by weight, the solid raw materials: 100 parts, the activator: 1-15 parts; wherein said solid raw materials comprise fly ash: 100 parts, high-alumina fly ash, bauxite and red mud: 6-18 parts, silica fume: 1-5 parts, surfactant: 0.1-3 parts, plasticizer: 6-24 parts; and said activator comprises alkali metal hydroxide: 5-20 parts and alkali metal silicate: 80-95 parts. The lightweight high-strength ceramsite product prepared has a density level of 700-1100 kg/m3 and cylindrical compressive strength of 10-20 MPa, and thus is not susceptible to damage.

Abstract: A lightweight high-strength ceramsite, comprising solid raw materials and activator as the raw materials, which can be respectively expressed in parts by weight, the solid raw materials: 100 parts, the activator: 1-15 parts; wherein said solid raw materials comprise fly ash: 100 parts, high-alumina fly ash, bauxite and red mud: 6-18 parts, silica fume: 1-5 parts, surfactant: 0.1-3 parts, plasticizer: 6-24 parts; and said activator comprises alkali metal hydroxide: 5-20 parts and alkali metal silicate: 80-95 parts. The lightweight high-strength ceramsite product prepared has a density level of 700-1100 kg/m3 and cylindrical compressive strength of 10-20 MPa, and thus is not susceptible to damage.

Abstract: This invention discloses the method for preparing desmosdumotin C, the series of desmosdumotin C derivatives and their manufactures, and the total synthesis of desmosdumotin B. The invention also discloses uses of the derivatives and pharmaceutical compositions containing the same in preparation of medicines for treatment of tumor or AIDS.

Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.

Abstract: This invention discloses the method for preparing desmosdumotin C, the series of desmosdumotin C derivatives and their manufactures, and the total synthesis of desmosdumotin B. The invention also discloses uses of the derivatives and pharmaceutical compositions containing the same in preparation of medicines for treatment of tumor or AIDS.

Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.

Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmeutical formulations thereof.

Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmeutical formulations thereof.

Abstract: Transparent access to networked resources identified with a resource locator that is at least partially obscured. When a resource locator is received, for example, by a proxy, client authorization to access the resource is validated. If the client is authorized, then the at least partial obscuring is do-obscured and the resource is retrieved from the resource manager according to the de-obscured resource locator. Even if the client is using a protocol that would normally identify the source of the resource, the resource is provided to the client as if it originated with the proxy. In such manner, the location of the resource manager may remain hidden.